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Abstract
Background: Low-dose ritonavir (RTV) boosts plasma amprenavir (APV) exposure. Little has been published on the
efficacy, tolerability, and safety of APV 600 mg/RTV 100 mg (APV600/RTV) twice daily (BID) compared to APV 1200 mg
BID (APV1200).
Methods: ESS40011 was a 24-week, multicenter, open-label, clinical trial in which antiretroviral therapy-naïve and -
experienced HIV-1-infected adults were randomized 3:1 to receive either APV600/RTV BID or APV1200 BID, in
combination with ≥ 2 non-protease inhibitor antiretroviral drugs. Non-inferiority of the APV600/RTV regimen to the
APV1200 regimen was established if the 95% lower confidence limit for the difference in proportion of patients achieving
HIV-1 RNA <200 copies/mL at week 24 with APV 600/RTV minus APV1200 was ≥-0.12. Late in the conduct of the trial,
patients not yet completing 24 weeks of therapy were given the option of continuing treatment for an additional 24-week
period.
Results: 211 patients were randomized, 158 to APV600/RTV and 53 to APV1200. At week 24, APV600/RTV was similar
to or better than APV1200 (HIV-1 RNA <200 copies/mL in 62% [73/118] vs 53% [20/38] of patients; intent-to-treat:
observed analysis). In the APV600/RTV arm, significantly more patients achieved HIV-1 RNA <50 copies/mL (48% [57/
118] vs 29% [11/38] with APV1200, P = 0.04), and greater mean reduction from baseline in HIV-1 RNA was observed (-
2.21 vs -1.59 log10 copies/mL, P = 0.028). The two treatment arms were similar with respect to mean overall change from
baseline in CD4+ count, frequency of drug-related grade 1–4 adverse events, and frequency of discontinuing treatment
due to adverse events (most commonly nausea, diarrhea, vomiting or fatigue; 7% vs 8%), although a lower proportion of
patients in the APV600/RTV arm experienced drug-related oral/perioral paresthesia (2% vs 8%). Eleven (73%) of 15
patients who had HIV-1 RNA <200 copies/mL at week 24 and chose to continue study treatment maintained this level
of virologic suppression at follow-up 24 weeks later.
Conclusions: APV600 RTV BID was similar to or better than APV1200 BID in virologic response. Virologic results in
a small number of patients who continued treatment for 24 weeks post-study suggest that virologic suppression with
APV600 RTV BID is durable.
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Background
Amprenavir (APV) is a potent protease inhibitor (PI) that
is used in combination with other antiretroviral drugs for
the treatment of antiretroviral-naïve and -experienced
adults and children with HIV infection [1–5]. APV offers
the convenience of twice-daily (BID) administration with
no food or fluid restrictions [6,7]. Preclinical and clinical
data suggest that APV has a lower potential to cause lipo-
dystrophy and metabolic abnormalities than other cur-
rently available PIs [8–10]. APV has a distinct resistance
profile that permits it to be considered as a treatment
option for either PI-naïve or PI-experienced patients [11].
In a 64-week trial in treatment-naïve patients (NZTA4002;
n = 302), APV 1200 mg, administered BID (APV1200)
with one abacavir 300 mg tablet and one lamivudine 150
mg/zidovudine 300 mg combination tablet (Combivir®),
was as effective as nelfinavir 750 mg three times daily plus
Combivir BID, with regard to the proportion of patients
achieving HIV-1 RNA <40 copies/mL at week 64: 77% vs
66% (as-treated analysis) [12]. However, many patients in
this trial withdrew prematurely because of adverse events
that may have been, in part, related to the high pill burden
(16 large 150 mg soft-gelatin capsules daily) associated
with APV dosing and excipients contained in the APV for-
mulation available at the time of the trial.
To reduce APV pill burden and possibly improve tolerabil-
ity of APV treatment, pharmacokinetic research efforts
have been directed at combining APV with the PI ritonavir
(RTV), which inhibits CYP3A4-mediated hepatic metabo-
lism of APV, thereby enhancing plasma APV exposure
[13–15]. The administration of RTV at the clinically sub-
therapeutic dosage of 100 mg BID was found to boost
APV plasma exposure to such a degree as to permit halving
the APV daily pill burden from 16 to 8 capsules/day, in
addition to maintaining the minimum plasma APV con-
centration (Cmin) over 24 hours well above the 50%
inhibitory concentrations (IC50) of patient-derived HIV-1
isolates [15]. A pharmacokinetic study in 20 HIV-infected
patients, PROF1004, showed that APV at the lower dosage
of 600 mg BID combined with RTV 100 mg BID (APV600/
RTV) resulted in a geometric mean steady-state APV Cmin
(1.92 µg/mL) over 6-fold higher than the Cmin resulting
from APV1200 (0.3 µg/mL) [16]. This Cmin was more than
13-fold higher than the IC50 of APV against HIV of antiret-
roviral-naïve patients (mean, 0.146 ± 0.125 µg/mL) and
over 2-fold higher than the IC50 of APV against HIV of
multi-PI-resistant patients (mean, 0.903 ± 0.846 µg/mL)
(IC50s adjusted for the 90% protein binding observed
with APV). Following APV600/RTV, the APV maximum
serum concentration (Cmax) has been reported to be
slightly lower (by 27%) than that observed with APV1200
[17], which may account for the RTV-boosted APV regi-
men being less likely to cause certain adverse events (e.g.,
oral/perioral paresthesia and headache) [18].
Since the above pharmacokinetic studies and others
involving pharmacokinetic modeling predictions were
conducted over only a short period (generally ≤ 14 days)
and in a small number of patients, there remained a need
to evaluate low-dose APV/RTV combinations in large pop-
ulations of HIV-1-infected patients over a therapeutically
relevant period. The purpose of ESS40011 was to compare
the efficacy, safety, and tolerability of APV 600 mg BID
plus RTV 100 mg BID (APV600/RTV) to APV 1200 mg BID
(APV1200) over 24 weeks in antiretroviral-naïve or -expe-
rienced HIV-infected patients who were receiving other
background antiretroviral drugs. Late in the study,
patients who had not yet completed 24 weeks of treat-
ment were given the option to continue treatment in a
subsequent 24-week extension phase to assess the dura-
bility of virologic response.
Methods
Patients
Male and non-pregnant, non-lactating female outpatients
were eligible for study enrollment if they were at least 18
years of age; had HIV-1 infection documented by HIV-1
antibody enzyme-linked immunosorbent assay (ELISA)
and confirmed by Western blot test, positive HIV-1 cul-
ture, positive HIV-1 serum antigen, or plasma viremia;
and CD4+ cell counts ≥ 50/mm3. Women of childbearing
potential had to have a negative serum β-human chori-
onic gonadotropin (HCG) pregnancy test at screening,
and had to be willing to use an adequate method of con-
traception during the study. Patients could be either
antiretroviral-naïve or -experienced. If patients were
antiretroviral-experienced, they had to be naïve to APV,
have a plasma HIV-1 RNA >1000 copies/mL, show sus-
ceptibility to APV and ≥ 2 other antiretroviral drugs, and
remain on their most recent treatment regimen until com-
pletion of the screening visit. For all drugs, susceptibility
was defined as an HIV isolate with <4.0-fold change in
IC50  (determined by VIRCOGEN™ [Tibotec-Virco NV,
Mechelen, Belgium], a virtual phenotype assay) in com-
parison to the control virus. Patients were excluded if they
had active Centers for Disease Control (CDC) Class C sta-
tus; could not comply with the study schedule; were in
another investigational drug study; were undergoing opi-
ate detoxification; had a malabsorption syndrome or pre-
existing condition that interfered with normal gastrointes-
tinal transit; had clinically significant laboratory abnor-
malities, required radiation therapy or cytotoxic
chemotherapy, or had received immunomodulating
agents, within 4 weeks pre-study; or had received an HIV-
1 immunotherapeutic vaccine within 3 months pre-study.
Patients were allowed to take pravastatin, fluvastatin,
cerivastatin, or atorvastatin for hyperlipidemia at the cau-
tionary discretion of the investigators, but were not
allowed to take lovastatin, simvastatin, or any other drugBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/10
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known to significantly affect metabolism by the cyto-
chrome P450 CYP3A4 enzyme system.
Study Design
In this multicenter, open-label clinical trial, patients were
first stratified according to prior antiretroviral therapy
exposure (i.e., naïve or experienced), then randomized
3:1 to treatment for 24 weeks with either APV 600 mg BID
plus RTV 100 mg BID or to APV 1200 mg BID in combi-
nation with ≥ 2 non-PI antiretroviral drugs. APV was sup-
plied as 150 mg soft-gelatin capsules of Agenerase®
(GlaxoSmithKline, Research Triangle Park, North Caro-
lina); thus, eight capsules were given for each 1200 mg
dose of APV and four capsules for each 600 mg dose. RTV
was supplied as 100 mg soft-gelatin capsules of Norvir®
(Abbott Laboratories, North Chicago, Illinois). Late in the
study, patients who had not yet completed 24 weeks of
treatment were given the option to continue treatment in
a subsequent 24-week extension phase to assess the dura-
bility of virologic response.
During the 6-week period prior to the start of the study,
candidates were screened for study eligibility, demogra-
phy, CDC classification, HIV risk factors, mode of HIV
transmission, antiretroviral therapy history, and medical
history, and given a physical examination. Prior to study
initiation, the ESS40011 study protocol was approved by
the Institutional Review Boards at each participating study
site. All participants provided written informed consent
before any study-related procedures were commenced.
The initial 24-week portion of the study was conducted
between June 13, 2000 and October 18, 2001 at 44 treat-
ment centers in the United States.
Efficacy and Safety Assessment
The primary efficacy parameter was the proportion of
patients with plasma HIV-1 RNA levels <200 copies/mL at
week 24. Plasma HIV-1 RNA was assessed by the Roche
Amplicor MONITOR Ultrasensitive assay (version 1.5;
lower limit of quantitation [LLOQ] 50 copies/mL and
quantitation range of 50 to 75,000 copies/mL, Roche
Diagnostics, Branchburg, New Jersey). Patients were clas-
sified as having reached a virologic endpoint if, at week
24, plasma HIV-1 RNA levels were ≥ 200 copies/mL; or if
the plasma HIV-1 RNA had not decreased by at least 0.5-
log10 from baseline at week 8, with confirmation at week
12.
Secondary efficacy measures included assessment of the
proportion of patients achieving HIV-1 RNA <50 copies/
mL (using the above mentioned assay); changes in CD4+
cell counts (measured by flow cytometry) compared with
baseline values; and progression of HIV disease from
baseline status to the occurrence of the first new event
involving a change in CDC class for each patient. Patients
who remained at their entry CDC class were considered to
be clinical non-progressors.
Change from baseline in plasma HIV-1 RNA levels was
assessed at weeks 4, 8, 12, and 24 in all patients, as well as
at weeks 32, 40 and 48 in patients who participated in the
treatment extension phase. CD4+ cell counts were
assessed at baseline, and at weeks 12 and 24. Patients had
plasma collected for genotype/virtual phenotype at
screening (for experienced patients only) and at the time
of virologic failure (results to be reported elsewhere).
Statistical Analysis
The study was powered to evaluate whether the virologic
efficacy (proportion of patients with plasma HIV-1 HIV
<200 copies/mL at week 24) in the APV 600/RTV arm was
at least as good (non-inferior) as in the APV1200 arm.
Non-inferiority of the APV600/RTV regimen to the
APV1200 regimen was established if the 95% lower confi-
dence limit (LCL) for the difference in proportion of
patients achieving HIV-1 RNA <200 copies/mL at week 24
with APV 600/RTV minus APV1200 was ≥-0.12. The non-
inferiority margin of 0.12 was chosen based on previous
regulatory studies and was pre-specified in the protocol.
Target enrollment was 198 in the APV600/RTV arm and
66 in the APV1200 arm. The primary analysis was made in
the intent-to-treat (ITT) population, which consisted of all
eligible patients who were randomized into the study
regardless of what treatment was actually received and the
eventual outcome of study participation. Two types of
analyses were performed: an ITT: observed analysis, in
which only available assessments were used (no imputa-
tion for missing values), regardless of whether the patient
was still receiving their original therapy; and an ITT: miss-
ing = failure (ITT: M = F) analysis, in which all missing val-
ues constituted failure. Comparisons between treatment
arms regarding proportion of patients achieving HIV-1
RNA <200 copies/mL and <50 copies/mL were made
using the Cochran-Mantel-Haenszel test controlling for
prior antiretroviral drug experience. Changes from base-
line in plasma HIV-1 RNA (log10 copies/mL) and CD4+
cell count, and average area under the curve minus base-
line (AAUCMB) in plasma HIV-1 RNA, were tabulated by
treatment arm and visit, then analyzed using analysis of
variance (ANOVA). The safety population consisted of all
patients who consumed at least 1 dose of study drug.
Safety parameters included incidence of treatment-limit-
ing toxicities (clinical and laboratory adverse events); and
change from baseline in selected laboratory variables at
weeks 4, 8, 12 and 24. Fisher's exact test was used to com-
pare adverse event rate and ANOVA was used to compare
change from baseline for laboratory variables between the
two treatment arms. A P value of <0.05 was considered
statistically significant. Statistical analyses were performed
using SAS version 6.12 (SAS Institute, Inc., Cary, NC).BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/10
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Results
Patient Characteristics and Disposition
A total of 211 patients enrolled; they were predominantly
male (87%), ethnically diverse (48% Caucasian, 37%
African American, 14% Hispanic), and had a mean age of
42 years, median baseline HIV-1 RNA level of 4.33 log10
copies/mL, and median baseline CD4+ cell count of 257
cells/mm3. Most of the study population was antiretrovi-
ral-experienced (81%). One hundred and fifty-eight (158)
patients were randomized to the APV600/RTV regimen
and 53 to the APV1200 regimen. The two treatment arms
did not differ with respect to any baseline characteristic
(Table 1). The most common background antiretroviral
regimens taken by patients in the APV600/RTV and
APV1200 treatment arms were stavudine/didanosine
(25% vs 30%), Combivir (19% for both arms), abacavir/
stavudine (11% for both arms), lamivudine/stavudine
(9% vs 4%), and abacavir/didanosine (5% vs 6%). A total
of 150 patients (71%) completed all 24 weeks of the
study, including a similar proportion of patients in the
APV600/RTV arm (72%) and APV1200 arm (68%). Rea-
sons for premature withdrawal from treatment were also
similar between the APV600/RTV and APV1200 arms,
except for fewer patients in the APV600/RTV arm
withdrawing due to protocol-defined virologic failure
(1% vs 6%) (Table 1). Antihyperlipidemic agents were
used by 1 patient in each treatment arm, neither of whom
had taken this type of medication pre-study. No deaths or
clinical progressions of HIV disease occurred. Twenty
patients enrolled into the extension phase, including 15
in the APV600/RTV arm and 5 in the APV1200 arm.
Virologic Measurements of Efficacy
At week 24, the proportion of patients with HIV-1 RNA
<200 copies/mL in the APV600/RTV arm and APV1200
arm was 46% (73/158) and 38% (20/53), respectively, in
the ITT: M = F analysis (Figure 1) and 62% (73/118) and
53% (20/38), respectively, in the ITT: observed analysis
(Figure 2). The APV600/RTV regimen proved to be similar
to or better than the APV1200 regimen because the 95%
LCL for the difference in proportions of patients achieving
HIV-1 RNA <200 copies/mL with APV600/RTV minus
APV1200 was ≥ -0.12 (-0.04 [ITT: M = F analysis] and -
0.06 [ITT: observed analysis]). The proportion of
Table 1: Baseline demographics and disease characteristics of the patients, and their study disposition
Characteristic APV 600 mg/RTV 100 mg BID (N = 158) APV 1200 mg BID (N = 53)
Age, years
Median 40 43
Range 25 – 63 29 – 62
Gender, No. (%)
Male 139 (88) 44 (83)
Female 19 (12) 9 (17)
Race, No. (%)
Caucasian 81 (51) 21 (40)
Black 58 (37) 20 (38)
Hispanic 18 (11) 11 (21)
Asian 1 (<1) 1 (2)
CDC classification
Caterory A 74 (47) 29 (55)
Category B 46 (29) 10 (19)
Category C 37 (24) 14 (26)
HIV-1 RNA, log10 copies/mL
Mean ± SD 4.33 ± 0.58 4.35 ± 0.66
Median (Range) 4.31 (2.98 – 5.88) 4.38 (2.74 – 5.81)
CD4+ cell count, cells/mm3
Mean ± SD 307 ± 187 327 ± 226
Median (Range) 271 (43 – 948) 255 (35 – 1054)
Premature withdrawal 44 (28) 17 (32)
Adverse event 11 (7) 4 (8)
Consent withdrawn 5 (3) 2 (4)
Lost to follow up 11 (7) 5 (9)
Insufficient CD4+ response 1 (<1) 0
Insufficient viral load response 4 (3) 1 (2)
Protocol-defined virological failure 2 (1) 3 (6)
Other 10 (6) 2 (4)
Abbreviations: APV, amprenavir; RTV, ritonavir; SD, standard deviationBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/10
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antiretroviral-naïve patients who achieved HIV-1 RNA
<200 copies/mL in the APV600/RTV arm was twice that
for the APV1200 arm in the ITT: M = F analysis (63% [19/
30] vs 30% [3/10], P = 0.141), and 26% higher in the ITT:
observed analysis (76% [19/25] vs 50% [3/6], P = 0.320).
In contrast, the proportions in antiretroviral-experienced
patients were similar in the treatment arms in both analy-
ses (ITT: M = F analysis: 42% [54/128] vs 40% [17/43], P
= 0.859; ITT: observed analysis: 58% [54/93] vs 53% [17/
32], P = 0.682).
Virologic findings using the more stringent virologic sup-
pression endpoint of HIV-1 RNA <50 copies/mL paral-
leled those with the <200 copies/mL endpoint, although
differences attained statistical significance. Thus, at week
24, significantly more patients in the APV600/RTV arm
than the APV1200 arm achieved HIV-1 RNA <50 copies/
mL (ITT: M = F analysis: 36% [57/158] vs 21% [11/53], P
= 0.039; ITT: observed analysis: 48% [57/118] vs 29%
[11/38], P = 0.042) (Figures 1 and 2, respectively). The
proportion of antiretroviral-naïve patients who achieved
HIV-1 RNA <50 copies/mL was 47% (14/30) in the
APV600/RTV arm and 20% (2/10) in the APV1200 arm (P
= 0.141), whereas the proportion of antiretroviral-experi-
enced patients who achieved HIV-1 RNA <50 copies/mL
was 34% (43/128) in the APV600/RTV arm and 21% (9/
43) in the APV1200 arm (P = 0.119) (ITT:M = F analysis).
In the ITT: observed analysis, mean reduction in HIV-1
RNA from baseline was significantly greater at week 24 in
the APV600/RTV arm than the APV1200 arm (-2.21 vs -
1.59 log10 copies/mL, P = 0.028) (Figure 3), as was the
mean AAUCMB in HIV-1 RNA in both the total popula-
tion (-1.56 vs -1.25 log10 copies/mL,  P  = 0.045) and
antiretroviral-naïve subgroup (-2.40 vs -1.60 log10 copies/
mL, P = 0.020). No significant differences were observed
between the APV600/RTV and APV1200 treatment arms
with respect to mean AAUCMB in HIV-1 RNA for the
antiretroviral-experienced subgroup (-1.40 vs -1.20 log10
copies/mL  P  = 0.209), or proportion of antiretroviral-
naïve patients achieving HIV-1 RNA <50 copies/mL (56%
vs 33%, P = 0.394) (ITT: observed analysis).
Of the 20 patients (15 in the APV600/RTV arm and 5 in
the APV1200 arm) enrolled into the extension phase, 15
(11 APV600/RTV, 4 APV1200) had HIV-1 RNA <200 cop-
ies/mL at week 24. Eleven (8 APV600/RTV, 3 APV1200) of
these 15 patients continued to have HIV-1 RNA levels
<200 copies/mL between week 24 and week 48, 3
rebounded, and 1 discontinued at week 32. Of the 5
patients who had HIV-1 RNA >200 copies/mL at week 24,
1 discontinued when an HIV-1 RNA of 186 copies/mL was
measured at week 32, 1 missed week 32 and 40 visits (but
had an HIV-1 RNA of 878 copies/mL at week 48), and 3
continued to have HIV-1 RNA >200 copies/mL from week
24 to week 48. In these 3 patients, HIV-1 RNA levels
ranged from 316 to 3645 copies/mL, 1247 to 5175 cop-
ies/mL, and 143 to 12,149 copies/mL, respectively,
between weeks 24 and 48.
Figure 1
Percentage of patients with plasma HIV-1 RNA levels <200 
copies/mL and <50 copies/mL in the intent-to-treat (ITT): 
missing = failure analysis.
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Figure 2
Percentage of patients with plasma HIV-1 RNA levels <200 
copies/mL and <50 copies/mL in the ITT: observed analysis.
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Immunologic Measurements of Efficacy
At baseline, the median CD4+ cell count in the APV600/
RTV and APV1200 arms was 271 and 255 cells/mm3,
respectively. Over the 24 weeks of the study, the median
CD4+ cell count remained higher than baseline, with
median elevations above baseline peaking at week 12 in
both treatment arms (+51 and +52 cells/mm3, respec-
tively) (Figure 3). At week 24, the median change from
baseline in CD4+ cell count in the APV600/RTV and
APV1200 arms was +35 and +46 cells/mm3, respectively,
and the final median CD4+ cell count was 321 and 346
cells/mm3, respectively. In patients who participated in
the 24-week extension phase, 12 of 15 patients in the
APV600/RTV arm and 4 of 5 in the APV1200 arm had a
median change from baseline in CD4+ cell count at week
48 of +156 cell/mm3, and +143 cell/mm3, respectively.
The final median CD4+ cell count in these patients was
404 and 407 cells/mm3, respectively. The remaining
patients did not have CD4+ data reported.
Safety
Table 2 shows the drug-related adverse events that were
reported in ≥ 5% of patients. Nausea, diarrhea, vomiting,
and fatigue were the most common adverse events in both
treatment arms. The incidence of drug-related oral/perio-
ral paresthesia was lower in the APV600/RTV treatment
arm than the APV1200 arm (2% vs 8%). No differences
between the APV600/RTV and APV1200 treatment arms
were observed regarding the frequency of drug-related
grade 1–4 adverse events (44% vs 45%), frequency of
discontinuing treatment due to adverse events (7% vs
8%), incidence of hyperglycemia (1 vs 0 patient), nonspe-
cific lipodystrophy (1 vs 0), buffalo hump (1 vs 0), or
hypercholesterolemia (1 vs 0). More cases of hypertriglyc-
eridemia were reported as adverse events in the APV600/
RTV arm (11 [7%] vs 0). However, review of laboratory
changes revealed that the incidence of grade 3–4 hyper-
triglyceridemia was the same (4%) in each treatment arm.
Discussion
The virological results of this study indicate that over a 24-
week treatment period the APV600/RTV regimen was sta-
tistically similar to or better than the APV1200 regimen
according to the <200 copies/mL endpoint criterion.
However, a significantly greater proportion of patients in
the APV600/RTV treatment arm achieved HIV-1 RNA <50
copies/mL. Greater reductions in plasma HIV-1 RNA
levels were also observed in patients receiving APV600/
RTV BID than those using APV1200 BID. The greater mag-
nitude of virologic suppression in the study population as
a whole with the APV600/RTV regimen was expected in
view of the results of earlier clinical pharmacokinetic stud-
ies showing a >6-fold higher Cmin level with APV600/RTV
BID compared with the APV1200 BID regimen [16].
Higher Cmin values achieved with RTV-boosting may be
critical in treating antiretroviral-experienced patients, par-
ticularly those with HIV isolates having increased IC50 val-
ues.
The proportion of antiretroviral-naïve patients who
achieved HIV-1 RNA <200 copies/mL in the APV600/RTV
arm was twice that for the APV1200 arm (63% vs 30%, P
= 0.141). No differences in virologic efficacy between
treatment arms were evident in the antiretroviral-experi-
enced subgroup (42% vs 40%, P = 0.859). It is possible
that proportionally more treatment-naïve patients may
have responded to APV600/RTV due to poorer or more
difficult adherence to the APV1200 regimen, but no
adherence checks were included in this study to verify this.
Although the <50 copies/mL endpoint criterion also
showed a higher proportion of antiretroviral-naïve
patients responding to APV600/RTV than to APV1200
(47% vs 20%), the differences were not statistically signif-
icant, possibly due to the small size of this subgroup. In
another study of APV600/RTV in antiretroviral-naïve
patients, Arasteh et al [19] reported a higher proportion of
patients achieving plasma HIV-1 RNA <50 copies/mL
(75%) than in the present study, perhaps due to the use of
only lamivudine and abacavir as background antiretrovi-
ral medication and to differences in their study popula-
tion relative to ours.
The proportion of antiretroviral-experienced patients in
the APV600/RTV treatment arm who achieved HIV-1 RNA
<200 copies/mL at 24 weeks (58% [ITT:observed
analysis]; 42% [ITT: M = F analysis]) was comparable to
Figure 3
Median change from baseline in plasma HIV-1 RNA levels and 
CD4+ cell counts in the ITT: observed analysis.
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that reported in antiretroviral-experienced patients at 24
weeks in the studies by Schooley et al [20] (ESS40006
[PEARL]) (69% [ITT:observed analysis]), but much higher
than that reported by Katlama et al [21] (31% [ITT: M = F
analysis]). Differences in virologic suppression between
the present study and the Katlama study may stem from
the use of other background agents and the far greater
antiretroviral experience and well-documented PI muta-
tions in Katlama's patients.
The 24-week extension phase showed that most patients
who had HIV-1 RNA <200 copies/mL at week 24
maintained this level of virologic suppression through
week 48. Thus, some indication of durability of viral sup-
pression might be gathered from these data, although the
number of patients evaluated in this study phase was
small. The durability of virologic response to APV600/
RTV was also suggested in an earlier study by Katlama et
al [21].
The increase in CD4+ cells observed at 24 weeks in the
APV600/RTV BID arm was not different from that in the
APV1200 arm. It was lower in magnitude than the CD4+
cell count increases reported for APV600/RTV arm at 24
weeks in antiretroviral-experienced patients in ESS40006
[20], and similar to that reported in heavily pre-treated
patients by Katlama et al [21] in a patient population with
comparable baseline disease characteristics (median HIV-
1 RNA of 4.5 log10/mL and CD4+ count of 227 cells/
mm3).
The safety profile of the APV600/RTV regimen was similar
to that of the APV1200 regimen with respect to the main
adverse events, which were gastrointestinal (GI) in nature
in both treatment arms. GI adverse events reported in the
APV600/RTV arm were possibly due to the addition of
RTV to the regimen, or because the reduction in pill bur-
den and, hence, in excipients was not great enough to
improve GI tolerance. The higher incidence of oral/perio-
ral paresthesia in the APV1200 treatment arm was most
likely due to the higher APV Cmax that occurs following
APV1200 dosing compared with APV600/RTV BID dosing
[17]. Although the incidence of headache has been shown
to increase with higher APV Cmax values [18], the inci-
dence of this adverse event did not differ between treat-
ment arms in this study. The higher incidence of
hypertriglyceridemia in the APV600/RTV arm was proba-
bly due to RTV, because this PI has been reported to cause
elevations in serum triglycerides [22]. Other studies of
RTV-boosted APV regimens have also reported that triglyc-
eride elevation is usually grade 1 or 2 in magnitude, and,
as in the present study, seldom necessitates treatment dis-
continuation or the addition of antihyperlipidemic drugs
to the patient's treatment plan [10,19].
This study evaluated a patient population that was ethni-
cally diverse, with just over half of the patients being
either African American or Hispanic. The inclusion of a
large proportion of African American and Hispanic
patients was deemed important because these are the pop-
ulations in whom the HIV epidemic is increasing the most
[23]. Earlier clinical trials have tended to underrepresent
these populations [24].
One limitation of our study was that no pharmacokinetic
analyses were performed to validate whether the RTV
dosage regimen co-administered with APV600 was effec-
tively boosting plasma APV exposure or Cmin levels. How-
Table 2: Drug-related adverse events of all grades that occurred in ≥ 5% of patients*
Event No. of Patients (%)
APV 600 mg/RTV 100 mg BID (N = 158) APV 1200 mg BID (N = 53)
Gastrointestinal
Nausea 31 (20) 10 (19)
Diarrhea 27 (17) 10 (19)
Vomiting 10 (6) 5 (9)
Non-site specific
Fatigue 11 (7) 4 (8)
Neurology
Headache 9 (6) 2 (4)
Paresthesia, oral/perioral 3 (2) 4 (8)
Endocrine and metabolic
Hypertriglyceridemia 11 (7) 0
Skin
Rashes 8 (5) 3 (6)
*Adverse events were classified as drug-related based on the investigators' assessment of causality.BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/10
Page 8 of 9
(page number not for citation purposes)
ever, ESS40006, which also evaluated the APV600/RTV
regimen over a 24-week period, did conduct a pharma-
cokinetic evaluation showing steady-state serum APV Cmin
values of 2.49 µg/mL (i.e., over 8-fold higher than that
usually achieved after the APV1200 regimen). Thus,
plasma APV levels well above the IC50s of most HIV iso-
lates were most likely achieved in ESS40011. Higher RTV
doses of 200 mg BID and 400 mg BID co-administered
with APV600 have resulted in no greater virologic sup-
pression than 100 mg BID [25], and raising the dose of
APV from 600 mg BID to 900 mg BID does not improve
efficacy either, although it may increase the incidence of
adverse events [20].
In conclusion, APV600/RTV BID was similar to or better
than APV1200 BID based on virologic results using the
200-copies/mL HIV-1 RNA endpoint. Of note, a signifi-
cantly greater proportion of patients in the APV600/RTV
treatment arm achieved HIV-1 RNA <50 copies/mL at
week 24, which was a secondary endpoint. Other benefi-
cial features of the APV600/RTV regimen, such as
improved dosing convenience and reduced pill burden,
need to be factored into decision making when APV600/
RTV is being considered by clinicians as a therapeutic
option for the treatment of either antiretroviral-naïve or -
experienced patients with HIV infection.
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